Clinical trial · Interventional
Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors
NCT05484687CI-TRIAL-00068469completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Surgical resection is the main treatment option for colorectal cancer patients. Surgery may enhance or accelerate tumor recurrence and metastasis. Multiple factors in the tumor microenvironment play important roles in tumor recurrence and metastasis, and modulating the tumor microenvironment can inhibit disease progression. Lidocaine has been found to inhibit tumor growth in animal experiments.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Tumors | Colorectal Neoplasm | ALIAS | 0.90 |
| Lidocaine | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lidocaine is used in radical resection of colorectal tumors.
- description
- Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
- interventionNames
- Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
Primary outcomes (1)
- measure
- the concentration of tumor micrometastasis markers were determined by ELISA
- timeFrame
- 3 days after surgery
- description
- the concentration of tumor micrometastasis markers such as CK20 was determined by ELISA
Secondary outcomes (4)
- measure
- the concentration of stress hormones were determined by ELISA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * colorectal tumor patients Exclusion Criteria: * Weight \<45kg and \>100kg * Sensitivity or hypersensitivity to lidocaine * Second or third degree heart block * Severe heart failure (ejection fraction \< 20%) * History of active rhythm disorder * Acute severe liver and kidney injury * History of uncontrolled seizures * History of acute porphyria.
References
Publications (0)
Data not yet available
No reference posted for this study.